Unknown

Dataset Information

0

Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype.


ABSTRACT: Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. These findings have therapeutic implications for improving stent biocompatibility.

SUBMITTER: Vanags LZ 

PROVIDER: S-EPMC6060078 | biostudies-other | 2018 Apr

REPOSITORIES: biostudies-other

altmetric image

Publications

Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype.

Vanags Laura Z LZ   Tan Joanne T M JTM   Tan Joanne T M JTM   Galougahi Keyvan K KK   Schaefer Andreas A   Wise Steven G SG   Murphy Andrew A   Ali Ziad A ZA   Bursill Christina A CA  

JACC. Basic to translational science 20180401 2


Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. These findings have therapeutic implications for improving stent biocompatibility. ...[more]

Similar Datasets

| S-EPMC5105062 | biostudies-literature
| S-EPMC6890749 | biostudies-literature
| S-EPMC6533301 | biostudies-literature
2021-09-04 | GSE182225 | GEO
| S-EPMC6632006 | biostudies-literature
| S-EPMC8106951 | biostudies-literature
| S-EPMC9750080 | biostudies-literature
| S-EPMC10567768 | biostudies-literature
| S-EPMC4395282 | biostudies-literature